Clinical Trial Update: Study of 3 Doses of ARD-0403 in Testosterone Deficient Men [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating three doses of ARD-0403 in testosterone-deficient men has completed. The study investigated ARD-0403 for hypogonadism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism

Drugs mentioned

• ARD-0403 (ARD-0403)

Snippet

Sponsor: Ardana Bioscience Ltd | Conditions: Hypogonadism | Phase 2 | Status: COMPLETED